Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 am Eastern Time NEW YORK – February 9, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central […]
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
NEW YORK – December 2, 2024 Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President […]